Pfizer Completes Metsera Deal to Expand Obesity Drug Pipeline

Pfizer acquisition news took center stage today as the company confirmed it has closed its purchase of Metsera, a clinical-stage biotech pushing new treatments for obesity and cardiometabolic disease.

The move marks a major step for Pfizer as it deepens its focus on a fast-growing therapeutic area.

Albert Bourla, Pfizer’s chairman and CEO, called the deal a defining moment. “This strategic milestone represents more than a transaction—it's a deliberate investment in the future of medicine. By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it,” he said. He added that the company is ready to pair Metsera’s science with Pfizer’s global reach to move these candidates to patients worldwide.

Also Read: Pfizer Beats Novo Nordisk in $10 Billion Metsera Deal

With the acquisition now complete, Pfizer gains a strong lineup of treatments that fit well with its Internal Medicine pipeline. These include MET-097i, a weekly and monthly injectable GLP-1 receptor agonist heading into phase 3 trials, and MET-233i, a monthly amylin analog now in phase 1. The portfolio also brings an oral GLP-1 candidate and multiple preclinical hormone-based programs.

Pfizer paid $65.60 per share in cash, valuing the deal at about $7 billion, plus a contingent value right of up to $20.65 per share tied to key clinical and regulatory milestones. Metsera’s stock will stop trading on NASDAQ after markets close today, and the company now operates as a Pfizer unit.

The company noted the Pfizer acquisition will be dilutive through 2030 as it invests in late-stage candidates. Updated financial guidance is expected later this year.